We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
- Authors
Allred, D Craig; Anderson, Stewart J; Paik, Soonmyung; Wickerham, D Lawrence; Nagtegaal, Iris D; Swain, Sandra M; Mamounas, Elefetherios P; Julian, Thomas B; Geyer, Charles E, Jr; Costantino, Joseph P; Land, Stephanie R; Wolmark, Norman
- Abstract
The NSABP (National Surgical Adjuvant Breast and Bowel Project) B-24 study demonstrated significant benefit with adjuvant tamoxifen in patients with ductal carcinoma in situ (DCIS) after lumpectomy and radiation. Patients were enrolled without knowledge of hormone receptor status. The current study retrospectively evaluated the relationship between receptors and response to tamoxifen.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Vol 30, Issue 12, p1268
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.34.0141